Clinical Trial Update: A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval. [Phase 1]

View source ↗

Summary

This document reports the withdrawal of a Phase 1 study evaluating two different repeat doses of GSK2190915 on the QTc interval in asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK2190915

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 1 | Status: WITHDRAWN